• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Coegin Pharma

3.45 SEK

-0.58 %

Less than 1K followers

COEGIN

NGM Growth Market

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
-0.58 %
+4.55 %
-5.74 %
-22.30 %
-29.45 %
+2.99 %
-64.15 %
-91.59 %
-89.16 %

Coegin Pharma is a Swedish biotechnology company in commercial phase, developing science-based innovations for hair and skin. The company's patented ingredient for hair growth is now available in products sold through selected partners. A peptide for natural skin pigmentation is also in development with a planned launch in the near future. Coegin Pharma is headquartered in Lund.

Read more
Market cap
98.64M SEK
Turnover
13.79K SEK
Revenue
79K
EBIT %
-25,888.61 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
19/8
2026

Interim report Q2'26

18/11
2026

Interim report Q3'26

25/2
2027

Annual report '26

All
Press releases
ShowingAll content types

Revenue and EBIT-%

Revenue K

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Press release6/16/2026, 7:30 AM

Coegin Pharma receives highly encouraging user feedback from Hårklinikken

Coegin Pharma
Press release6/15/2026, 7:00 AM

Coegin Pharma enters distribution agreement with LYKO for launch of first VEXIENNE® Follicopeptide® product

Coegin Pharma
Press release6/2/2026, 12:30 PM

Coegin Pharma provides NPP-4 development update - INCI registration filed and commercialization preparations on track.

Coegin Pharma

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release5/21/2026, 9:00 AM

Communiqué from the Annual General Meeting of Coegin Pharma AB (publ)

Coegin Pharma
Regulatory press release5/21/2026, 7:45 AM

Coegin Pharma AB publishes its interim report for the first quarter of 2026

Coegin Pharma
Press release5/20/2026, 7:30 AM

Coegin Pharma's partner Mercapharm prepares major commercial launch of Follicopeptide® in Poland

Coegin Pharma
Regulatory press release4/29/2026, 12:00 PM

Coegin Pharma AB publishes Annual Report for 2025

Coegin Pharma
Regulatory press release4/20/2026, 7:20 AM

Notice of annual general meeting in Coegin Pharma AB (publ)

Coegin Pharma
Regulatory press release4/20/2026, 7:20 AM

Kallelse till årsstämma i Coegin Pharma AB (publ)

Coegin Pharma
Press release4/16/2026, 12:53 PM

Coegin Pharma expands commercial strategy with own-brand distribution model - launches VEXIENNE®

Coegin Pharma
Press release3/26/2026, 1:25 PM

Coegin Pharma's management acquires shares in the company

Coegin Pharma
Press release3/4/2026, 1:30 PM

Coegin Pharma receives first purchase order for new scalp serum

Coegin Pharma
Press release3/2/2026, 10:30 AM

Coegin Pharma accelerates Follicopeptide® portfolio expansion with a new high-performance scalp serum

Coegin Pharma
Regulatory press release2/26/2026, 1:30 PM

Coegin Pharma AB (publ) publishes its year-end report for 2025

Coegin Pharma
Regulatory press release2/19/2026, 5:40 PM

Coegin Pharma carries out directed issues totalling approx. SEK 12.1 million and strengthens the Company's liquidity position

Coegin Pharma
Press release1/2/2026, 8:30 AM

Coegin Pharma provides an operational and strategic update

Coegin Pharma
Press release12/22/2025, 12:30 PM

Coegin Pharma appoints worldleading pigmentation and hair-biology expert Professor Desmond J. Tobin as Scientific Advisor

Coegin Pharma
Press release12/19/2025, 8:25 AM

Coegin Pharma completes first delivery of Follicopeptide products to Hårklinikken

Coegin Pharma
Press release12/12/2025, 10:50 AM

Coegin Pharma delivers first commercial batch of Follicopeptide products to Gents

Coegin Pharma
Regulatory press release11/27/2025, 8:45 AM

Coegin Pharma's Nomination Committee appointed for the 2026 Annual General Meeting

Coegin Pharma